Pfizer Inc. (PFE) Yield on Cost (YOC): 6.72%
The yield on cost (YOC) for Pfizer Inc. (PFE) is 6.72%.
PFE Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
6.72%
Yield on Cost for PFE
PFE now pays $1.72 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-08) | $33.42 | 5.15% |
| 5 years ago(2021-06-16) | $39.30 | 4.38% |
| 3 years ago(2023-06-06) | $38.37 | 4.48% |
| 1 year ago(2025-06-10) | $24.30 | 7.08% |
| Buying today(at $25.60) | $25.60 | 6.72% |
If you buy today and the dividend keeps growing
Projection: starting from today's 6.72% yield, assuming the dividend keeps compounding at its historical 2.5% rate. Boards set dividends each year, so actual figures will differ.
Today
6.72%
In 3 years
7.41%
In 5 years
7.91%
In 10 years
9.30%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Pfizer Inc. (PFE).
Starting Yield
6.72%
Ending YOC
9.73%
Year 15 Dividend
$2.49
Cum. Dividends Recd.
$31.61
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $1.72 | — | 6.72% | $0.00 |
| Year 1 | $1.76 | +2.50% | 6.89% | $1.76 |
| Year 2 | $1.81 | +2.50% | 7.06% | $3.57 |
| Year 3 | $1.85 | +2.50% | 7.24% | $5.42 |
| Year 4 | $1.90 | +2.50% | 7.42% | $7.32 |
| Year 5 | $1.95 | +2.50% | 7.60% | $9.27 |
| Year 6 | $1.99 | +2.50% | 7.79% | $11.26 |
| Year 7 | $2.04 | +2.50% | 7.99% | $13.31 |
| Year 8 | $2.10 | +2.50% | 8.19% | $15.40 |
| Year 9 | $2.15 | +2.50% | 8.39% | $17.55 |
| Year 10 | $2.20 | +2.50% | 8.60% | $19.75 |
| Year 11 | $2.26 | +2.50% | 8.82% | $22.01 |
| Year 12 | $2.31 | +2.50% | 9.04% | $24.32 |
| Year 13 | $2.37 | +2.50% | 9.26% | $26.69 |
| Year 14 | $2.43 | +2.50% | 9.49% | $29.12 |
| Year 15 | $2.49 | +2.50% | 9.73% | $31.61 |
Pfizer Inc. Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Pfizer Inc. (PFE)?
- The yield on cost (YOC) for PFE stock is 6.72%.
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla